French Cohort for the Study of Non-invasive Tests of Liver Lesions in NAFLD/NASH (FreSH Cohort)

Inclusion Criteria: * NAFLD diagnosis defined by the presence of at least two of the following elements: * Liver steatosis (hyperechoic liver on hepatic ultrasound, quantification \> 5.6 % by spectroscopy or MRI) * Presence of one metabolic risk factor: * BMI ≥ 25 kg/m2 or waist circumference ≥ 94 cm (male) / ≥ 80 cm (female) * Antihypertensive treatment or systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg * Antidiabetic treatment or fasting blood glucose ≥ 5.6 mmol/l * Lipid-lowering treatment or triglycerides ≥ 1.71 mmol/l or HDL cholesterol \<1.1 mmol/l (male) / \<1.3 mmol/l (female) * Dysmetabolic hyperferritinemia * Anomaly in the liver enzyme test or liver function tests * Indication for liver biopsy in the clinical management of the patient * Obtaining the signature of the consent to participate in the study Exclusion Criteria: * Steatogenic treatment (corticosteroids, tamoxifen, amiodarone, methotrexate) * Excessive alcohol consumption in the last 5 years (\> 210 g / week for men or \> 140 g / week for women) * Chronic infection with hepatitis B or C * Any evidence of other concomitant chronic liver disease * Decompensated cirrhosis (ascites, digestive bleeding due to varicose vein rupture, liver failure, hepatocellular failure, hepato-renal syndrome) * Hepatocellular carcinoma * Pregnant, breastfeeding or parturient women * Persons deprived of their liberty by judicial or administrative decision * Persons subject to legal protection measures * Persons unable to consent * Refusal to participate